BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

Waters Corporation. (2/28/05). "Press Release: Waters Corporation Chooses IBM eServer OpenPower Server Solutions to Drive Latest Line of Proteomics Discovery Systems". Orlando, FL.

Organisation Organisation Waters Corporation (NYSE: WAT)
  Group Waters (Group)
Product Product  Waters Protein Expression System (LC/MS system)

Waters Corporation announced today that it has selected IBM's eServer™ OpenPower™ 720 system to drive its line of proteomics discovery systems.

The IBM OpenPower 720 system will power the Waters ProteinLynxTM Global SERVER software platform -- an integrated family of tools for automated protein identification and characterization - and Waters Protein Expression Informatics - specialized software for the Waters Protein Expression System, a UPLC/Q-Tof™ MS system solution for (isotope) label-free quantitative proteomics and biomarker applications. The IBM OpenPower 720 system enables the multi-threaded, 64-bit capabilities of the ProteinLynx Global SERVER™ and Protein Expression Informatics to be fully leveraged on Linux® platforms.

"Our decision to use IBM's OpenPower 720 system was based on the increased speed, efficiency and productivity it brings to our key proteomics technologies, particularly in Linux-based environments," said Tim Riley, Vice President of Proteomics Business Development for Waters. "We are continuously looking to be more efficient and responsive to the needs of our customers. IBM has global reach and its products can help Waters provide the high performance tools that meet the demands of these leading proteomics applications."

"As Linux matures to support mission critical applications, IBM's new family of OpenPower systems takes Linux to the next level," said Brian Connors, Vice President, Linux on POWER, at IBM. "We are pleased that Waters has selected OpenPower as their platform of choice for its proteomics discovery systems."

Waters instruments for proteomics applications and biomarker discovery feature specialized bio-informatics software tools and are used by the world's leading pharmaceutical, biotechnology and research organizations.

About Waters Corporation

Waters Corporation holds worldwide leading positions in three complementary analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis. These market segments account for $4.5 - $5.0 billion of the overall $20+ billion analytical instrumentation market.

About IBM Healthcare and Life Sciences

The goal of IBM Healthcare and Life Sciences is to rapidly bring IT technology to customers and IBM Business Partners in the fields of pharmaceutical research, biotechnology, genomics, health and other life science industries. IBM is a proven leader in data integration, supercomputing, high performance storage, e-business and information technology services. Long-term projects at IBM Research Centers and the IBM Deep Computing Institute foster collaboration with life science companies bringing domain expertise and innovative technologies to the development of life science solutions. To learn more about IBM Healthcare and Life Science Solutions and IBM Business Partners, visit the IBM Web site at or contact an IBM Healthcare and Life Sciences specialist at

Waters, ProteinLynx Global SERVER, Q-Tof, and ProteinLynx are trademarks of Waters Corporation.

IBM, eServer, OpenPower, and POWER5 are trademarks or registered trademarks of International Business Machines Corporation in the United States, other countries or both..

UNIX is a registered trademark in the United States and other countries, licensed exclusively through X/Open Company, Limited.

(1) All statements regarding IBM's future direction and intent are subject to change or withdrawal without notice, and represent goals and objectives only.

Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including delays in product introductions, loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products, and foreign exchange fluctuations. Such factors are discussed in detail in the Company's filings with the Securities and Exchange Commission and, in particular, the Company's Annual Report on Form 10-K for the year ended December 31, 2003.

Record changed: 2016-03-19


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Waters (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px